Genmab — Januar 2013
-
Biotekbranchens enfant terrible ligner en børsdarling
Tillid: Biotekselskabet Genmab har snart genvundet tillid hos investorerne. Det er formentlig slut med at bede om flere penge.
(medwatch.dk)
-
man må sige at de har fået modnet en del sælgere heroppe. Når de er renset ud, så kommer der en pæn stigning tror jeg
-
Takker. Så kan vi sove roligt igen.
-
-
Det er først lige begyndt

-
@repsac good point. Men mon det er for småt?
-
@gentogen hvilket forsøg refererer de til?
-
-
Analysis of the effect of OFA with fludarabine and mafosfamide showed the expected synergism between these two standard chemotherapeutic agents in whole blood, previously demonstrated with purified cells, and a clear additive effect of OFA at 10 μg/ml, which added ∼25% lysis, that is more than that obtained with RTX (5% increased lysis).
-
Kære Gentogen, vil du ikke nok være fortælle mig og sikkert også en masse andre hvad et helt nøjagtig betyder, jeg fornemmer at det er godt for GENMAB .. men har det noget at gøre med at vi kan regne med at det blir godkendt som 1rd line, du ved det som AKA taler om på den sidste video ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind